Mark Carrier is researcher and the chair of the hemostasis and malignancies subcommittee of ISTH. During this interview he goes through what the subcommittee does, why their activities are important and how does it interlace with ICTHIC. He has two big phase 3 studies now recruiting, the AVERT study ad the PERI-OP, which he hopes they will bring favourable results. He believes in the importance of real-world data to be implemented with the results of the studies, so that said knowledge can be applied to the whole patient population.
Categories
Multimedia, Video